MCID: BRN120
MIFTS: 42

Bronchus Cancer

Categories: Cancer diseases, Respiratory diseases

Aliases & Classifications for Bronchus Cancer

MalaCards integrated aliases for Bronchus Cancer:

Name: Bronchus Cancer 12 15
Malignant Neoplasm of Bronchus and Lung 12 32
Bronchogenic Carcinoma 17 70
Bronchus Carcinoma 12 15
Malignant Neoplasm of Bronchus or Lung 12
Bc - Bronchogenic Carcinoma 12
Carcinoma, Bronchogenic 44
Bronchial Neoplasms 70

Classifications:



External Ids:

Disease Ontology 12 DOID:1325 DOID:3904
ICD9CM 34 162.9
MeSH 44 D002283
NCIt 50 C35875
SNOMED-CT 67 187875007 254622008
ICD10 32 C34 C34.9
UMLS 70 C0006264 C0007121 C0348343

Summaries for Bronchus Cancer

Disease Ontology : 12 A respiratory system cancer that is located in the bronchus.

MalaCards based summary : Bronchus Cancer, also known as malignant neoplasm of bronchus and lung, is related to mediastinal cancer and small cell cancer of the lung, and has symptoms including fever, dyspnea and hemoptysis. An important gene associated with Bronchus Cancer is ENO2 (Enolase 2). The drugs Gemcitabine and Pemetrexed have been mentioned in the context of this disorder. Affiliated tissues include bronchus, lung and thyroid.

Related Diseases for Bronchus Cancer

Diseases in the Bronchus Cancer family:

Bronchus Carcinoma in Situ

Diseases related to Bronchus Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 333)
# Related Disease Score Top Affiliating Genes
1 mediastinal cancer 30.1 ENO2 CEACAM5
2 small cell cancer of the lung 30.1 GRP ENO2 CEACAM5
3 myoblastoma 30.0 ENO2 CEACAM5
4 lung benign neoplasm 29.9 GRP FHIT ENO2
5 endobronchial lipoma 29.9 GRP ENO2
6 neuroendocrine carcinoma 29.3 GRP ENO2 CEACAM5
7 main bronchus cancer 11.1
8 bronchus carcinoma in situ 11.1
9 bronchus mucoepidermoid carcinoma 11.1
10 pulmonary blastoma 10.7
11 pleuropulmonary blastoma type 1 10.7
12 pleuropulmonary blastoma type 2 10.7
13 pleuropulmonary blastoma type 3 10.7
14 pleuropulmonary blastoma 10.6
15 well-differentiated fetal adenocarcinoma of the lung 10.6
16 lung cancer 10.6
17 pneumothorax 10.5
18 pleural empyema 10.5
19 in situ carcinoma 10.4
20 sarcoidosis 1 10.4
21 pneumothorax, primary spontaneous 10.3
22 pulmonary fibrosis 10.3
23 neuropathy 10.3
24 asbestosis 10.3
25 asbestos intoxication 10.3
26 respiratory failure 10.2
27 hemopericardium 10.2
28 pericardial effusion 10.2
29 alopecia 10.2
30 adult respiratory distress syndrome 10.2
31 nephrotic syndrome 10.2
32 benign mesothelioma 10.2
33 pulmonary coin lesion 10.2
34 actinomycosis 10.2
35 cerebellar degeneration 10.2
36 vaginal glandular tumor 10.2 ENO2 CEACAM5
37 gastric small cell carcinoma 10.2 ENO2 CEACAM5
38 vulvar apocrine adenocarcinoma 10.2 ENO2 CEACAM5
39 paratesticular lipoma 10.2 ENO2 CEACAM5
40 lipoma of spermatic cord 10.2 ENO2 CEACAM5
41 lambert syndrome 10.2
42 aspergillosis 10.2
43 lambert-eaton myasthenic syndrome 10.2
44 neutropenia 10.2
45 pleural disease 10.2
46 pericarditis 10.2
47 bronchitis 10.2
48 exophthalmos 10.2
49 granulocytopenia 10.2
50 paraneoplastic syndromes 10.2

Graphical network of the top 20 diseases related to Bronchus Cancer:



Diseases related to Bronchus Cancer

Symptoms & Phenotypes for Bronchus Cancer

UMLS symptoms related to Bronchus Cancer:


fever; dyspnea; hemoptysis; coughing

Drugs & Therapeutics for Bronchus Cancer

Drugs for Bronchus Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 68)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 3 95058-81-4 60750
2
Pemetrexed Approved, Investigational Phase 3 150399-23-8, 137281-23-3 446556 60843
3
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
4
Vinorelbine Approved, Investigational Phase 3 71486-22-1 60780 44424639
5
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
6
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
7
Pembrolizumab Approved Phase 3 1374853-91-4
8
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
9
Tyrosine Approved, Investigational, Nutraceutical Phase 3 60-18-4 6057
10 Tubulin Modulators Phase 3
11 Folic Acid Antagonists Phase 3
12 Vitamin B9 Phase 3
13 Immunosuppressive Agents Phase 3
14 Antimitotic Agents Phase 3
15 Folate Phase 3
16 Vitamin B Complex Phase 3
17 Immunologic Factors Phase 3
18 Anti-Infective Agents Phase 3
19 Antimetabolites Phase 3
20 Antiviral Agents Phase 3
21 Antineoplastic Agents, Immunological Phase 3
22 Vitamins Phase 3
23
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
24
Fluticasone Approved, Experimental Phase 2 90566-53-3 62924
25
Acetylcysteine Approved, Investigational Phase 2 616-91-1 12035
26
Osimertinib Approved Phase 1, Phase 2 1421373-65-0 71496458
27
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
28
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
29
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
30
Glucosamine Approved, Investigational Phase 2 3416-24-8 439213
31 Respiratory System Agents Phase 2
32 Anti-Asthmatic Agents Phase 2
33 Anti-Allergic Agents Phase 2
34 Anti-Inflammatory Agents Phase 2
35 Bronchodilator Agents Phase 2
36 Dermatologic Agents Phase 2
37 Vaccines Phase 2
38 Antidotes Phase 2
39 Antioxidants Phase 2
40 Protective Agents Phase 2
41 Expectorants Phase 2
42 N-monoacetylcystine Phase 2
43 Protein Kinase Inhibitors Phase 1, Phase 2
44 Mitogens Phase 2
45 Immunoglobulins Phase 2
46 Antibodies Phase 2
47 Antibodies, Monoclonal Phase 2
48 Pharmaceutical Solutions Phase 2
49 Albumin-Bound Paclitaxel Phase 2
50 Immunoglobulins, Intravenous Phase 2

Interventional clinical trials:

(show all 48)
# Name Status NCT ID Phase Drugs
1 A Randomized Controlled Trial of Endobronchial or Endoscopic Ultrasound as a First Test in the Diagnosis and Staging of Lung Cancer Completed NCT00652769 Phase 3
2 A Phase III, Randomized, Open-Label, Multi-center Study of SHR-1210(Anti-PD-1 Antibody) in Combination With Pemetrexed and Carboplatin as First Line Therapy in Subjects With Advanced/Metastatic Non-squamous Non-small Cell Lung Cancer Completed NCT03134872 Phase 3 Carboplatin;Pemetrexed
3 Comparison Study of Post-operative Pain and Quality of Life Between Subxiphoid and Intercostal Vedio-assisted Thoracic Surgery for Radical Lung Cancer Resection Completed NCT03331588 Phase 3
4 Randomized Phase III Multicenter Trial of Customized Chemotherapy Versus Standard of Care for1st Line Treatment of Elderly Patients With Advanced Non-Small-Cell Lung Cancer Recruiting NCT03402048 Phase 3 Carboplatin;Gemcitabine;Pemetrexed;Docetaxel;Vinorelbine
5 A Randomized, Open-Label, Phase 3 Study of Pralsetinib Versus Standard of Care for First Line Treatment of RET Fusion-positive, Metastatic Non-Small Cell Lung Cancer Recruiting NCT04222972 Phase 3 Pralsetinib;Carboplatin;Cisplatin;Pemetrexed;Pembrolizumab;Gemcitabine
6 An Open-label, Single-arm, Multi-center, Phase 2 Study to Evaluate SHR-1210(Anti-PD-1 Antibody) in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer Unknown status NCT03085069 Phase 2
7 A Phase II Trial of Gefitinib in Squamous NSCLC Patients Who Failed First-Line Chemotherapy Unknown status NCT01485809 Phase 2 Gefitinib
8 The Influence of Fluticasone Inhalation on Intermediate Markers of Carcinogenesis in the Bronchial Epithelium of a High Risk Population : A Double Blind Placebo-Controlled Randomised Phase II Study Completed NCT00407264 Phase 2 Fluticasone propionate
9 Phase II Study of Lucanix™ (TGF-beta2 Antisense Gene Modified Allogeneic Tumor Cell Vaccine) in Patients With Stages II-IV Non-Small Cell Lung Cancer Completed NCT01058785 Phase 2
10 Effect of N-Acetylcysteine on Skeletal Muscle in Cachectic Cancer Patients Undergoing a Resistance Training Program (Phase 2 Study) Completed NCT00196885 Phase 2 N-acetylcysteine
11 A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 and Cobimetinib in Adult Participants With Relapsed/Refractory Solid Tumors and a Phase 1b Study of RMC-4630 With Osimertinib in Participants With EGFR Mutation Positive, Locally Advanced or Metastatic NSCLC Recruiting NCT03989115 Phase 1, Phase 2 RMC-4630;Cobimetinib;Drug: Osimertinib
12 A Phase 1/2 Study of the Highly-selective RET Inhibitor, BLU-667, in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer (NSCLC) and Other Advanced Solid Tumors Recruiting NCT03037385 Phase 1, Phase 2 pralsetinib (BLU-667)
13 A Randomized, Phase II Trial of Icotinib Versus Observation as Adjuvant Treatment in Stage IB Non-Small Cell Lung Cancer Harboring Activating Epidermal Growth Factor Receptor Mutation Recruiting NCT02264210 Phase 2 Icotinib
14 A Phase II Trial of Atezolizumab Plus Induction Chemotherapy (CT) Plus Chemo-radiotherapy and Atezolizumab Maintenance Therapy in Non-resectable Stage IIIA-IIIB Non-small Cell Lung Cancer (NSCLC) Patients Not yet recruiting NCT04776447 Phase 2 Carboplatin;Placlitaxel;Atezolizumab
15 Thorakoskopische Handheld-SPECT Gesteuerte Ektomie Von Radioaktiv-markierten Pulmonalen Rundherden. Proof of Feasibility of Thoracoscopic Ectomy of Radioactively Marked Pulmonary Nodules With the Help of Free-hand SPECT. Terminated NCT02050724 Phase 2 Radioactive labelling of pulmonary nodules
16 Phase 1 Study of 18F-Al-NOTA-PRGD2 in Cancer Diagnostics Unknown status NCT02441972 Phase 1 18F-Al-NOTA-PRGD2 PET/CT
17 A Phase 1, Randomized, Open-Label, Continuation Study of Entinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumors (SNDX-275-0141, MK3475-460/KEYNOTE-460) Unknown status NCT02909452 Phase 1 Entinostat;Pembrolizumab
18 Diagnostic Efficacy of Virtual Bronchoscopy Completed NCT00001515 Phase 1
19 A Phase I Study Light Dose for Photodynamic Therapy (PDT) Using 2-[1-hexyloxyethyl]-2 Devinyl Pyropheophorbide-a (HPPH) for Treatment of Non-Small Cell Carcinoma in Situ or Non-Small Cell Microinvasive Bronchogenic Carcinoma: A Dose Ranging Study Completed NCT00526461 Phase 1 HPPH
20 A Phase I Study of Photodynamic Therapy (PDT) Combined With High Dose Rate (HDR) Brachytherapy for Patients With Obstructive Bronchogenic Carcinoma Completed NCT00014066 Phase 1 hematoporphyrin derivative
21 Phase I Trial of Motexafin Gadolinium (MGd) in Combination With Docetaxel and Cisplatin for Treatment of Non-Small Cell Lung Cancer (NSCLC) Completed NCT00102505 Phase 1 Motexafin Gadolinium Injection
22 A Phase 1 Cardiac Safety Study of Entinostat in Men and Women With Advanced Solid Tumors Completed NCT02897778 Phase 1 Entinostat
23 An Open-label, Multicenter, Phase I Dose-escalation Trial of EGF816 and Trametinib in Patients With Non-small Cell Lung Cancer and Acquired EGFR p.T790M-positive Resistance to 1st or 2nd Generation EGFR TKI Therapy Remark: According to Version V02_0 of the Protocol, Patients May Also be Eligible if EGFR TKI-treatment naïve, EGFR p.T790M-negative at Progression While on EGFR TKI Therapy or After Progression While on Osimertinib Treatment Recruiting NCT03516214 Phase 1 EGF816;Trametinib
24 A Multi-centre Observational Study on Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients Under Gefitinib Treatment Unknown status NCT02804100
25 CT Scan Guide Percutaneous Biopsy of Lytic Bone Metastases of Lung Cancer : Pathology Diagnosis and Molecular Biology Unknown status NCT03386916
26 Measurement of the Quality: Application to Lung Resection for Cancer Using a National PMSI Database Unknown status NCT02877043
27 Prevalence of Sleep-disordered Breathing in Patients With a Newly Diagnosed Non Small Cell Lung Cancer Unknown status NCT02648087
28 Incidence of Sleep Apnea Syndrome (SAS) in Patients With Bronchial Carcinoma Unknown status NCT02270853
29 Influence of Whole Body Electromyostimulation and Nutritional Therapy for Patients With Esophageal and Bronchial Carcinoma in Curative and Palliative Treatment Unknown status NCT03274349
30 Cost-consequence Analysis of Parenchymal Stapling Device Versus Hand-sewing for Pulmonary Lobectomy in Lung Disease: A Randomized Controlled Trial Completed NCT01575314
31 Study of the Modification of the Fixation of FDG, F-Miso and FLT Measured in PET/CT at Patients Before and in the Course of Exclusive Radiotherapy or Concomitant Radiochemotherapy for Primitive Bronchial Cancer Completed NCT01261585
32 Assessment of a Novel, Fast and Automatic CT-to-patient Registration Method During Navigated Bronchoscopy and Endobronchial Ultrasound Bronchoscopy (EBUS) Completed NCT02493023
33 Ultra-Violet Fluorescence Bronchial Cancer Location Completed NCT02533518
34 Feasibility of Immunotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting - ImHADom Completed NCT03786653
35 Circulating and Local Expression Levels of Survivin and Fibulin-3 in Benign and Malignant Respiratory Diseases Completed NCT04413292
36 Defining PET / CT Protocols With Optimized F18-FDG (Fluorodeoxyglucose) Dose, Focusing on Reduced Radiation Dose and Improved Image Quality Completed NCT02378337
37 LUng CAncer focuS - Long Term Non-interventional Monitoring of Diagnostic and Treatment Patterns in Patients With Bronchogenic Carcinoma (LUCAS) Recruiting NCT04228237
38 Assessment of a Novel, Fast and Automatic CT-to-patient Registration Method During Navigated Bronchoscopy and Endobronchial Ultrasound Bronchoscopy (EBUS) Recruiting NCT02745002
39 Fraxinus- Assessment of an Open Source Virtual Bronchoscopic Navigation System Recruiting NCT03745859
40 Rehabilitation by Effort for Patients With Advanced Bronchial Cancer Recruiting NCT03684486
41 Evaluation of a Remotely Guided Physical Preparation by a Physical Activity Teacher Adapted With the Help of a Smartwatch Before Bronchial Cancer Surgery Recruiting NCT04667065
42 Randomisierte Studie Zum Nutzen Eines Fitnesstracker Basierten Aktivitätstrainings während Einer Strahlentherapeutischen Behandlung (OnkoFit II Studie) Recruiting NCT04517019
43 Kinetics of Circulating Tumoral Cells in Bronchial Primitive Cancer Active, not recruiting NCT03328559
44 trūFreeze® Spray Cryotherapy Patient Registry Active, not recruiting NCT01802203
45 Wirksamkeit Der Versorgung in Onkologischen Zentren Enrolling by invitation NCT04334239
46 An External Control, Observational, Retrospective Study Assessing the Effect of Pralsetinib Compared With Best Available Therapy for Patients With RET-Fusion Positive Advanced Non-Small Cell Lung Cancer Enrolling by invitation NCT04697446
47 Feasibility of Immunotherapy Plus Chemotherapy Administration to Patients With Bronchial Cancer in a Hospital-at- Home Setting - CombHADom Not yet recruiting NCT04802902
48 Biological Study of Feasibility Concerning the Research for Mutation of the Gene of EGFR and for K-Ras in Circulating Tumoral Cells(CTCs) of the Patients Carriers of Metastatic Non Small Cells Bronchial Carcinomas Terminated NCT01380795 Early Phase 1

Search NIH Clinical Center for Bronchus Cancer

Inferred drug relations via UMLS 70 / NDF-RT 51 :


PROFIMER SODIUM

Cochrane evidence based reviews: carcinoma, bronchogenic

Genetic Tests for Bronchus Cancer

Anatomical Context for Bronchus Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Bronchus Cancer:

19
Bronchus

MalaCards organs/tissues related to Bronchus Cancer:

40
Lung, Thyroid, Myeloid, Colon, Bronchial Epithelium, Skeletal Muscle, Kidney

Publications for Bronchus Cancer

Articles related to Bronchus Cancer:

(show top 50) (show all 98)
# Title Authors PMID Year
1
Assessment of Trends in Second Primary Cancers in Patients With Metastatic Melanoma From 2005 to 2016. 61
33295975 2020
2
Development of 5D3-DM1: A Novel Anti-Prostate-Specific Membrane Antigen Antibody-Drug Conjugate for PSMA-Positive Prostate Cancer Therapy. 61
32803984 2020
3
Distress among African American and White adults with cancer in Louisiana. 61
31322062 2020
4
Impact of Prior Cancer on the Prognosis of Patients With Laryngeal Cancer: A Population-Based Study Using the Surveillance, Epidemiology, and End Results Database. 61
33194627 2020
5
Erratum to updated statistics of lung and bronchus cancer in United States (2018). 61
31019804 2019
6
[An airy feeling]. 61
30945831 2019
7
Problems to affect long-term survival for breast cancer patients: An observational study of subsequent lung/bronchus malignancies. 61
30278574 2018
8
Regional variation in lung and bronchus cancer survival in the US using mortality-to-incidence ratios. 61
30390926 2018
9
Annual Report to the Nation on the Status of Cancer, part I: National cancer statistics. 61
29786848 2018
10
Capture of tobacco use among population-based registries: Findings from 10 National Program of Cancer Registries states. 61
29579317 2018
11
Early estimates of cancer incidence for 2015: Expanding to include estimates for white and black races. 61
29509274 2018
12
The impact of self- and physician-administered cancer treatment on work productivity and healthcare utilization. 61
28559004 2018
13
Positive Surgical Margins in the 10 Most Common Solid Cancers. 61
29632347 2018
14
Updated statistics of lung and bronchus cancer in United States (2018). 61
29708136 2018
15
The Impact of Multiple Primary Rules on Cancer Statistics in Canada, 1992 to 2012. 61
30183692 2018
16
Increased incidence of respiratory tract cancers in people living near Portland cement plants in Korea. 61
28707127 2017
17
Distribution of Cancer by Sex and Site in Nepal 61
28670003 2017
18
Extensions to Multivariate Space Time Mixture Modeling of Small Area Cancer Data. 61
28486417 2017
19
Space-time variation of respiratory cancers in South Carolina: a flexible multivariate mixture modeling approach to risk estimation. 61
27653555 2017
20
Dosimetric impact of an air passage on intraluminal brachytherapy for bronchus cancer. 61
27605630 2016
21
White-Black Differences in Cancer Incidence, Stage at Diagnosis, and Survival among Adults Aged 85 Years and Older in the United States. 61
27528599 2016
22
Trends in Lung and Bronchus, Prostate, Female Breast, and Colon and Rectum Cancers Incidence and Mortality in Oklahoma and the United States from 1999 to 2012. 61
27885304 2016
23
Five-Year Cancer Survival Rates in Oklahoma from 1997 to 2008. 61
27890941 2016
24
Incidence rates for lung and bronchus cancer of Japanese in Japan and in the United States from the Cancer Incidence in Five Continents. 61
27380807 2016
25
Stat Bite Percentage of New Cases by Age Group for Lung and Bronchus Cancer (2008-2012). 61
31608414 2016
26
Racial and Gender Disparities in Incidence of Lung and Bronchus Cancer in the United States: A Longitudinal Analysis. 61
27685944 2016
27
Brachytherapy in the treatment of lung cancer - a valuable solution. 61
26622233 2015
28
Early estimates of SEER cancer incidence for 2012: Approaches, opportunities, and cautions for obtaining preliminary estimates of cancer incidence. 61
25739953 2015
29
Trend Analysis of Cancer Mortality and Incidence in Panama, Using Joinpoint Regression Analysis. 61
26091467 2015
30
Mindfulness-based stress reduction teachers, practice characteristics, cancer incidence, and health: a nationwide ecological description. 61
25887555 2015
31
Project update: evaluating the community health legacy of WWI chemical weapons testing. 61
24610560 2014
32
Prostate cancer incidence and mortality in the Spanish section of the European Randomized Study of Screening for Prostate Cancer (ERSPC). 61
24614694 2014
33
Malignant neoplasms of respiratory and intrathoracic organs (C30-C39) in the Osijek-Baranja County, Croatia. 61
25145000 2014
34
[Hospital undertaking of patients with a resection of lung cancer]. 61
24034457 2013
35
Cancer incidence in elderly West Virginians. 61
24294704 2013
36
A class of transformation covariate regression models for estimating the excess hazard in relative survival analysis. 61
23492766 2013
37
Differences in incidence rates and early detection of cancer among non-Hispanic and Hispanic Whites in the United States. 61
23914422 2013
38
Understanding population-based site-specific cancer incidence rates in the USA. 61
21874603 2012
39
Lung and bronchus cancer in Puerto Rico: changes in incidence and mortality rates by histology and sex during 1987-2003: comment on the article by Rivas et al. 61
22783701 2012
40
Lung and bronchus cancer in Puerto Rico: changes in incidence and mortality rates by histology and sex during 1987-2003. 61
22263297 2011
41
The quarter that changed the world. 61
20382647 2010
42
Sex disparities in cancer incidence by period and age. 61
19293308 2009
43
Superior vena cava syndrome in a man with situs inversus totalis and left main bronchus cancer. 61
19507488 2009
44
Towards a more comprehensive understanding of cancer burden in North Carolina: priorities for intervention. 61
18828316 2008
45
Tobacco control indicators and lung cancer rates in young adults by state in the United States. 61
18218813 2008
46
Lung and bronchus cancer disparities in South Carolina: epidemiology and strategies for prevention. 61
17319229 2006
47
Methylation and repeats in silent and nonsense mutations of p53. 61
16620878 2006
48
Discrepancies in cancer mortality estimates. 61
16624657 2006
49
Increased use of colorectal cancer tests--United States, 2002 and 2004. 61
16557215 2006
50
Stat bite: Mortality from lung and bronchus cancer by race/ethnicity, 1998-2002. 61
16449672 2006

Variations for Bronchus Cancer

Cosmic variations for Bronchus Cancer:

9 (show top 50) (show all 99)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM121875541 TP53 lung,bronchus,carcinoma,NS c.422G>A p.R141H 17:7673802-7673802 6
2 COSM121875983 TP53 lung,bronchus,carcinoma,NS c.347G>A p.R116Q 17:7674220-7674220 6
3 COSM144013089 TP53 lung,bronchus,carcinoma,NS c.785G>A p.R262H 17:7673802-7673802 6
4 COSM87933590 TP53 lung,bronchus,carcinoma,NS c.524G>T p.R175L 17:7675088-7675088 6
5 COSM142837352 TP53 lung,bronchus,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 6
6 COSM121908505 TP53 lung,bronchus,carcinoma,NS c.128G>T p.R43L 17:7675088-7675088 6
7 COSM143943797 TP53 lung,bronchus,carcinoma,NS c.266G>A p.R89Q 17:7674220-7674220 6
8 COSM121878352 TP53 lung,bronchus,carcinoma,NS c.422G>T p.R141L 17:7673802-7673802 6
9 COSM105620276 TP53 lung,bronchus,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 6
10 COSM143370869 TP53 lung,bronchus,carcinoma,NS c.626G>A p.R209Q 17:7674220-7674220 6
11 COSM93185256 TP53 lung,bronchus,carcinoma,NS c.818G>T p.R273L 17:7673802-7673802 6
12 COSM144039863 TP53 lung,bronchus,carcinoma,NS c.491G>T p.R164L 17:7675088-7675088 6
13 COSM106052890 TP53 lung,bronchus,carcinoma,NS c.818G>A p.R273H 17:7673802-7673802 6
14 COSM144651115 TP53 lung,bronchus,carcinoma,NS c.626G>A p.R209Q 17:7674220-7674220 6
15 COSM142838493 TP53 lung,bronchus,carcinoma,NS c.818G>T p.R273L 17:7673802-7673802 6
16 COSM122271559 TP53 lung,bronchus,carcinoma,NS c.347G>A p.R116Q 17:7674220-7674220 6
17 COSM121876459 TP53 lung,bronchus,carcinoma,NS c.346C>T p.R116W 17:7674221-7674221 6
18 COSM143971019 TP53 lung,bronchus,carcinoma,NS c.47G>T p.R16L 17:7675088-7675088 6
19 COSM142559879 TP53 lung,bronchus,carcinoma,NS c.701G>A p.R234H 17:7673802-7673802 6
20 COSM145019802 TP53 lung,bronchus,carcinoma,NS c.701G>T p.R234L 17:7673802-7673802 6
21 COSM144109717 TP53 lung,bronchus,carcinoma,NS c.47G>T p.R16L 17:7675088-7675088 6
22 COSM143156843 TP53 lung,bronchus,carcinoma,NS c.266G>A p.R89Q 17:7674220-7674220 6
23 COSM142561698 TP53 lung,bronchus,carcinoma,NS c.701G>T p.R234L 17:7673802-7673802 6
24 COSM106054865 TP53 lung,bronchus,carcinoma,NS c.818G>T p.R273L 17:7673802-7673802 6
25 COSM143156594 TP53 lung,bronchus,carcinoma,NS c.341G>A p.R114H 17:7673802-7673802 6
26 COSM105619828 TP53 lung,bronchus,carcinoma,NS c.782+379G>A p.? 17:7673802-7673802 6
27 COSM111760154 TP53 lung,bronchus,carcinoma,NS c.818G>T p.R273L 17:7673802-7673802 6
28 COSM143944147 TP53 lung,bronchus,carcinoma,NS c.265C>T p.R89W 17:7674221-7674221 6
29 COSM145017657 TP53 lung,bronchus,carcinoma,NS c.626G>A p.R209Q 17:7674220-7674220 6
30 COSM144310429 TP53 lung,bronchus,carcinoma,NS c.625C>T p.R209W 17:7674221-7674221 6
31 COSM144013676 TP53 lung,bronchus,carcinoma,NS c.709C>T p.R237W 17:7674221-7674221 6
32 COSM122271820 TP53 lung,bronchus,carcinoma,NS c.346C>T p.R116W 17:7674221-7674221 6
33 COSM145017944 TP53 lung,bronchus,carcinoma,NS c.625C>T p.R209W 17:7674221-7674221 6
34 COSM122300550 TP53 lung,bronchus,carcinoma,NS c.128G>T p.R43L 17:7675088-7675088 6
35 COSM145017297 TP53 lung,bronchus,carcinoma,NS c.701G>A p.R234H 17:7673802-7673802 6
36 COSM143943546 TP53 lung,bronchus,carcinoma,NS c.341G>A p.R114H 17:7673802-7673802 6
37 COSM87898351 TP53 lung,bronchus,carcinoma,NS c.743G>A p.R248Q 17:7674220-7674220 6
38 COSM106053434 TP53 lung,bronchus,carcinoma,NS c.742C>T p.R248W 17:7674221-7674221 6
39 COSM122734399 TP53 lung,bronchus,carcinoma,NS c.346C>T p.R116W 17:7674221-7674221 6
40 COSM112253879 TP53 lung,bronchus,carcinoma,NS c.742C>T p.R248W 17:7674221-7674221 6
41 COSM93183975 TP53 lung,bronchus,carcinoma,NS c.742C>T p.R248W 17:7674221-7674221 6
42 COSM144310203 TP53 lung,bronchus,carcinoma,NS c.626G>A p.R209Q 17:7674220-7674220 6
43 COSM122764387 TP53 lung,bronchus,carcinoma,NS c.128G>T p.R43L 17:7675088-7675088 6
44 COSM112255033 TP53 lung,bronchus,carcinoma,NS c.818G>T p.R273L 17:7673802-7673802 6
45 COSM105622149 TP53 lung,bronchus,carcinoma,NS c.782+379G>T p.? 17:7673802-7673802 6
46 COSM142590565 TP53 lung,bronchus,carcinoma,NS c.407G>T p.R136L 17:7675088-7675088 6
47 COSM122735595 TP53 lung,bronchus,carcinoma,NS c.422G>T p.R141L 17:7673802-7673802 6
48 COSM144086947 TP53 lung,bronchus,carcinoma,NS c.341G>A p.R114H 17:7673802-7673802 6
49 COSM143158314 TP53 lung,bronchus,carcinoma,NS c.341G>T p.R114L 17:7673802-7673802 6
50 COSM111788646 TP53 lung,bronchus,carcinoma,NS c.524G>T p.R175L 17:7675088-7675088 6

Expression for Bronchus Cancer

Search GEO for disease gene expression data for Bronchus Cancer.

Pathways for Bronchus Cancer

GO Terms for Bronchus Cancer

Sources for Bronchus Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....